Haitao Guo, PhD
Associate Professor of Microbiology & Immunology
Dr. Guo received a B.S (majored in Virology) in 1996 and a Ph.D (majored in Microbiology) in 2001 from Wuhan University, China. From 2002 to 2004, he did his postdoctoral training in Fox Chase Cancer Center, Philadelphia, where he started his research on hepatitis B virus (HBV). Then he joined Drexel University College of Medicine as a member of faculty and continued to conduct research on HBV for another 9 years. In 2014, he was appointed as an Associate Professor in the Department of Microbiology and Immunology, Indiana University School of Medicine (IUSM). Dr. Guo's research is focused on molecular virology, virus-host interactions, innate control of virus infection, and antiviral development. As a principal investigator, his research has been continuously funded by NIH and other funding sources. He has published more than 50 research and review articles, 1 book, and 3 patents. He serves as editor and editorial board member for many scientific journals, including PLoS, Journal of Virology and Hepatology. Dr. Guo is a member of the American Society for Microbiology and a lifetime member of the American Society for Virology. He is the co-chair of Virology Working Group of the International Coalition to Eliminate Hepatitis B (ICE-HBV), the co-organizer of 2015 International Meeting on Molecular Biology of Hepatitis B Viruses, and a standing member of the NIH Virology B Study Section. Dr. Guo is the Bruce Witte Fellow of Hepatitis B Foundation and the IUSM Showalter Scholar. He is the recipient of 2017 IUPUI Research Frontiers Trailblazer Award.
Long Q, Yan R, Hu J, Cai D, Mitra B, Kim ES, Marchetti A, Zhang H, Wang S, Liu Y, Huang A, Guo H. The role of host DNA ligases in hepadnavirus covalently closed circular DNA formation. PLoS Pathogens 2017, 13: e1006784.
Hong X, Kim ES, Guo H. Epigenetic Regulation of Hepatitis B Virus Covalently Closed Circular DNA: Implications for Epigenetic Therapy against Chronic Hepatitis B. Hepatology 2017, 66: 2066-77.
Liu Y, Nie H, Mao R, Mitra B, Cai D, Yan R, Guo JT, Block TM, Mechti N, Guo H. Interferon-inducible Ribonuclease ISG20 Inhibits Hepatitis B Virus Replication through Directly Binding to the epsilon Stem-loop Structure of Viral RNA. PLoS Pathogens 2017, 13: e1006296.
Mitra B, Guo H. Hepatitis B Virus X Protein Crosses Out Smc5/6 Complex to Maintain cccDNA Transcription. Hepatology 2016, 64:2246-49.
Cai D, Wang X, Yan R, Mao R, Liu Y, Ji C, Cuconati A, Guo H. Establishment of an Inducible HBV Stable Cell Line that Expresses cccDNA-dependent Epitope-tagged HBeAg for Screening of cccDNA Modulators. Antiviral Research 2016, 132: 26-37.
Yan R, Zhao X, Cai D, Liu Y, Block TM, Guo JT, Guo H. Interferon-inducible Protein Tetherin Inhibits Hepatitis B Virus Virion Secretion. Journal of Virology 2015, 89: 9200-12.
Mao R, Nie H, Cai D, Zhang J, Liu H, Yan R, Cuconati A, Block TM, Guo JT, Guo H. Inhibition of Hepatitis B Virus Replication by the Host Zinc Finger Antiviral Protein. PLoS Pathogens 2013, 9: e1003494.
Cai D, Mills C, Yu W, Yan R, Aldrich CE, Saputelli JR, Mason WS, Xu X, Guo JT, Block TM, Cuconati A, Guo H. Identification of the Disubstituted Sulfonamides as Specific Inhibitors of Hepatitis B Virus Covalently Closed Circular DNA Formation. Antimicrobial Agents and Chemotherapy 2012, 56: 4277-88.
Mao R, Zhang J, Jiang D, Cai D, Levy J, Cuconati A, Block TM, Guo JT, Guo H. Indoleamine 2, 3-dioxygenase mediates the Antiviral Effect of Gamma Interferon against Hepatitis B Virus in Human Hepatocyte-derived Cells. Journal of Virology 2011, 85: 1048-57.
Dr.Guo’s laboratory focuses on the viral pathogenesis of hepatitis B virus and antiviral discovery.
Hepatitis B virus (HBV) is the etiologic agent of viral hepatitis B, a disease affecting approximately 350 million people worldwide who suffer the high risk of liver failure, cirrhosis and liver cancer. My laboratory aims at understanding the molecular mechanisms of HBV DNA replication and morphogenesis, with special focus on the biosynthesis and regulation of HBV covalently closed circular (ccc) DNA, which is the persistent form of HBV infection, and is the culprit for the failure of current antiviral therapies. Making use of the HBV cccDNA reporter cell line systems recently established by us, we are screening small molecule compound libraries for cccDNA inhibitors in a high throughput fashion, and two identified cccDNA formation inhibitors are currently under preclinical development. In addition, we are studying the innate immunity and oncogenic signaling pathways that regulate HBV replication, as well as identification and characterization of host restriction factors that inhibit HBV infection and propagation in human hepatocytes.
Establishment of an inducible HBV stable cell line that expresses cccDNA-dependent epitope-tagged HBeAg for screening of cccDNA modulators.
Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
Identification of hydrolyzable tannins (punicalagin, punicalin and geraniin) as novel inhibitors of hepatitis B virus covalently closed circular DNA.
A novel method for nucleos(t)ide analogues susceptibility assay of hepatitis B virus by viral polymerase transcomplementation.
Molecular Biology and GeneticsCourse Number: G716
Fundamental Concepts of Infection and PathogenesisCourse Number: G728
Current Topics in MicroorganismsCourse Number: J829
Host DenfenseCourse Number: MEDX-650
2015 Co-Organizer 31th International Meeting of Molecular Biology of Hepatitis B Viruses 2016-date Member IUSM IBMG Ph.D Program Admission Committee 2016-date Member IUPUI Institutional Biosafety Committee 2016-date Co-Chair Virology Working Group of International Coalition to Eliminate Hepatitis B
American Society for Virology
Desc: Research Frontier Trailblazer Award
Desc: Showalter Scholar
Org: Hepatitis B Foundation
Desc: Bruce Witte Fellow